Ropinirole for restless legs syndrome: a placebo-controlled crossover trial.
The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.
Adler
C H
CH
Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, AZ 85259, USA. cadler@mayo.edu
Hauser
R A
RA
Sethi
K
K
Caviness
J N
JN
Marlor
L
L
Anderson
W M
WM
Hentz
J G
JG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018592:Cross-Over Studies; D004244:Dizziness / Q000139:chemically induced; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012148:Restless Legs Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole